scholarly journals Intrastent hematoma after treatment with a drug eluting balloon for in-stent restenosis: a case report

2021 ◽  
Author(s):  
Xu-Lin Hong ◽  
Guo-Sheng Fu ◽  
Zhan-Lu Li ◽  
Wen-Bin Zhang
Keyword(s):  
Case Report ◽  
Cutting Balloon ◽  
Stent Restenosis ◽  
Case Summary ◽  
Back Ground ◽  
Drug Eluting ◽  
Drug Eluting Balloon ◽  
Ivus Imaging ◽  
Insight Into ◽  
In Stent Restenosis

Abstract Back ground Intrastent hematoma after dilatation of in-stent restenosis is rarely reported and the optimal treatment for this condition remains unclear. Case summary We present the case of an 87-year-old man with in-stent subtotal occlusion of left circumflex (LCX). He experienced chest pain after drug eluting balloon (DEB) was released in the stent. Intravascular ultrasound (IVUS) revealed intrastent hematoma, which was not relieved with a cutting balloon but completely sealed by an Endeavor Resolute stent. Discussion Intrastent hematoma after dilatation of in-stent restenosis is rare. Reimplantation of stent seems the best method to solve this problem. IVUS imaging may provide insight into the cause of in-stent restenosis and guide the treatment.

Drug-eluting Balloons in Coronary Artery Disease – Current and Future Perspectives

2012 ◽  
Vol 8 (1) ◽  
pp. 56 ◽  
Author(s):  
Anouar Belkacemi ◽  
Pierfrancesco Agostoni ◽  
Michiel Voskuil ◽  
Pieter Doevendans ◽  
Pieter Stella ◽  
...  
Keyword(s):  
Small Vessel Disease ◽  
Percutaneous Treatment ◽  
Added Value ◽  
High Concentration ◽  
Diffuse Disease ◽  
Stent Restenosis ◽  
Alternative Treatment Option ◽  
Drug Eluting ◽  
Drug Eluting Balloon ◽  
In Stent Restenosis

Percutaneous treatment of complex coronary lesions, such as small-vessel disease, diabetes and long diffuse disease, remain hampered by suboptimal results, even with the use of drug-eluting stents (DES). The paclitaxel drug-eluting balloon (DEB) is an interesting emerging device that optimises clinical outcomes in these specific lesions. The DEB may become a viable alternative treatment option for the inhibition of coronary restenosis and subsequent revascularisation, as it allows local release of a high-concentration antirestenotic drug, paclitaxel, into the coronary vessel without using a metal scaffold or durable polymers. Several studies have already shown promising and consistent results in the treatment of in-stent restenosis. The DEB has demonstrated its added value compared with certain DES. Inspired by these results, an increasing number of studies have been started in different coronary lesion subsets to explore the value of the DEB in a broader range of lesions. It will be interesting to see whether the DEB will find more indications beyond in-stent restenosis treatment. Moreover, will all DEBs offer the same added value, or will there be differences in efficacy among the DEBs produced by the various manufacturers? As was the case in the development of DES, now the puzzle pieces have to be put together for DEB.

scholarly journals Efficacy of Drug-Eluting Balloon in the Treatment of Ostial Left Anterior Descending Artery In-Stent Restenosis

2014 ◽  
Vol 22 (2) ◽  
pp. 183-187
Author(s):  
Guy Fernando de Almeida Prado ◽  
Cristiano Guedes Bezerral ◽  
Gustavo Martins Pereira Alves ◽  
Marcio Augusto Meirelles Truffa ◽  
Expedito Eustaquio Ribeiro da Silva ◽  
...  
Keyword(s):  
Left Anterior Descending Artery ◽  
Stent Restenosis ◽  
Drug Eluting ◽  
Drug Eluting Balloon ◽  
In Stent Restenosis

scholarly journals Drug-eluting balloon treatment in femoropopliteal in-stent restenosis of different lengths

2020 ◽  
Vol 28 (3) ◽  
pp. 460-466
Author(s):  
Berkan Özpak
Keyword(s):  
Stent Restenosis ◽  
Significant Difference ◽  
Stent Length ◽  
Drug Eluting ◽  
Group 3 ◽  
Group 2 ◽  
Drug Eluting Balloon ◽  
One Year ◽  
In Stent Restenosis ◽  
Group 1

Background: In this study, we present one-year results of drug-eluting balloon treatment of femoropopliteal in-stent restenosis. Methods: A total of 62 patients (48 males, 14 females; mean age 64.2±9.1 years; range, 54 to 81 years) who underwent drug-eluting balloon stenting for femoropopliteal in-stent restenosis between August 2013 and October 2017 were included in the study. The patients were classified into three groups based on the narrowing length of stenosis in the stents. Group/Class 1 (n=17): narrowing <1/2 of the stent length; Group/Class 2 (n=22): narrowing >1/2 of the stent length, not totally occluded; and Group/Class 3 (n=23): totally occluded. In-stent restenosis was treated with drug-eluting balloon treatment. Results: There was a significant difference among all classes in terms of in-stent restenosis. The length of stenosis was a predictor for in-stent restenosis. The mean stent length was 107.7±24.6 mm in Group 1, 164.6±17.9 mm in Group 2, and 180±19.3 mm in Group 3. For non-occluded in-stent restenosis, restenosis rate at one year after balloon angioplasty was 47.1% in Group 1, 86.4% in Group 2, and 95.7% in Group 3. Femoropopliteal bypass was performed in five patients in whom treatment failed. None of the patients required amputation. Conclusion: The length of in-stent restenosis in the femoropopliteal arterial stents is an important predictor for recurrent stenosis, when re-flow is achieved with drug-eluting balloons.

Sign in / Sign up

Export Citation Format

Share Document